Puma Biotechnology (PBYI) Earning Somewhat Positive Press Coverage, Study Finds
Media headlines about Puma Biotechnology (NASDAQ:PBYI) have trended somewhat positive on Wednesday, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Puma Biotechnology earned a news impact score of 0.13 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.0877325826557 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Puma Biotechnology Inc (PBYI) Downgraded by BidaskClub to Buy (americanbankingnews.com)
- Zacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) Will Post Quarterly Sales of $18.05 Million (americanbankingnews.com)
- Puma Biotech (PBYI) Says Breast Cancer Drug to be Made Available in Australia, New Zealand and South East Asia (streetinsider.com)
- New Early- Breast Cancer Drug to be Made Available in Australia, New Zealand and South East Asia Following License Deal (finance.yahoo.com)
- Puma Biotechnology Inc (PBYI) Expected to Post Earnings of -$2.04 Per Share (americanbankingnews.com)
Puma Biotechnology (NASDAQ:PBYI) traded down $2.75 during midday trading on Wednesday, reaching $102.10. The company had a trading volume of 480,200 shares, compared to its average volume of 1,101,406. Puma Biotechnology has a 1-year low of $28.35 and a 1-year high of $136.90.
Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) EPS for the quarter, topping the Zacks’ consensus estimate of ($2.50) by $0.43. The business had revenue of $6.10 million for the quarter, compared to the consensus estimate of $3.78 million. During the same quarter last year, the company earned ($1.11) earnings per share. analysts anticipate that Puma Biotechnology will post -8.19 earnings per share for the current year.
Several research firms have recently weighed in on PBYI. BidaskClub lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 14th. Credit Suisse Group upped their price objective on Puma Biotechnology from $136.00 to $142.00 and gave the company an “outperform” rating in a research note on Friday, November 10th. Barclays reiterated a “buy” rating and issued a $122.00 price objective (up from $103.00) on shares of Puma Biotechnology in a research note on Friday, November 10th. Citigroup upped their price objective on Puma Biotechnology from $156.00 to $164.00 and gave the company a “buy” rating in a research note on Friday, November 10th. Finally, Royal Bank Of Canada lowered their price objective on Puma Biotechnology from $108.00 to $92.00 and set a “sector perform” rating on the stock in a research note on Friday, November 10th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $130.67.
In related news, SVP Richard Paul Bryce sold 15,000 shares of the stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $120.00, for a total transaction of $1,800,000.00. Following the sale, the senior vice president now directly owns 42,239 shares in the company, valued at approximately $5,068,680. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 21.10% of the stock is owned by corporate insiders.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.